Talphera Inc. (TLPH)
NASDAQ: TLPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TLPH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $40.80M
- EPS (TTM)
- -$0.21
- Dividend yield
- None
- 52-week range
- 0.69 – 1.57
- Day range
- 0.7181 – 0.84
- Volume / Avg
- 325.22K / 144.13K
- Beta
- —
- Shares outstanding
- 51.96M
52-week range
TLPH stock today
Shares of Talphera (TLPH) finished higher on Nov 20 at $0.7852, a gain of 6.25% or $0.0462 per share, versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 325.22K shares, a sign of unusually heavy trading. At this level, TLPH sits near the bottom of its 52-week range of $0.69 to $1.57: 50.0% below the high, set on Nov 24, 2025 and 13.8% above the low.
TLPH is down 31.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 41.4%. Talphera has posted a net loss over the last twelve months (EPS of -$0.21), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Talphera
Company profileTalphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Vincent J. Angotti
- Headquarters
- San Mateo, CA
- Employees
- 12
- IPO year
- 2011
- Website
- talphera.com
Financial highlights
Full financialsIn fiscal 2025, Talphera generated $28,000 in revenue, up 0.0% from fiscal 2024. Talphera reported a net loss of $14.3 million, compared with a loss of $13.0 million a year earlier. Operating margin was -48157.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $28.00K | $0 | $651.00K | $0 | $2.82M |
| Growth | — | -100.00% | — | -100.00% | -47.97% |
| Net income | $-14.29M | $-13.00M | $-18.40M | $47.76M | $-35.10M |
| EPS (diluted) | — | — | $-1.29 | $5.72 | $-5.86 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$3.13+298.62%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.11 vs $-0.06
- Surprise
- -83.33%
TLPH news
All TLPH newsTalphera peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELTXElicio Therapeutics Inc. | 1.45 | -3.33% | $41.05M | vs TLPH |
| MREOMereo BioPharma Group plc ADR | 0.26 | -5.45% | $41.52M | vs TLPH |
| BMEABiomea Fusion Inc. | 0.5744 | -2.38% | $41.75M | vs TLPH |
| OSTXOS Therapies Incorporated | 0.803 | -2.12% | $42.00M | vs TLPH |
| DWTXDogwood Therapeutics Inc. | 1.04 | -2.36% | $39.57M | vs TLPH |
| INCRIntercure Ltd. | 3.24 | -7.69% | $42.03M | vs TLPH |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 2.06 | -15.40% | $42.45M | vs TLPH |
| SPROSpero Therapeutics Inc. | 0.742 | -10.20% | $43.23M | vs TLPH |
Indexes, lists and sector
Talphera stock FAQ
What is Talphera's stock price today?
TLPH last traded at $0.7852 as of Nov 20, 4:00 PM EST, up 6.25% on the day. Prices are delayed at least 15 minutes.
Does Talphera pay a dividend?
No. Talphera does not currently pay a regular cash dividend.
Who is Talphera's CEO?
Mr. Vincent J. Angotti is the chief executive officer of Talphera Inc., which has about 12 employees.
Has TLPH ever split its stock?
Yes. The most recent TLPH stock split was a 1-for-20 split on Oct 26, 2022.
What is the TLPH 52-week high?
The 52-week high for TLPH is $1.57 and the 52-week low is $0.69. The stock is currently 50.0% below its high.